FindTrial
Sign In

A retrospective real-world study on the safety, effectiveness and economics of domestic and imported vancomycin anti-infective therapy

A retrospective real-world study on the safety, effectiveness and economics of domestic and imported vancomycin anti-infective therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100047847
Enrollment
Unknown
Registered
2021-06-27
Start date
2021-07-01
Completion date
Unknown
Last updated
2022-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infectious disease

Interventions

Laikexin Group:N/A
Vancocin group:N/A

Sponsors

Nanjing University Medical School Affiliated Nanjing Drum Tower Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients admitted to Nanjing University Medical School Affiliated Nanjing Drum Tower Hospital from January 1, 2013 to December 31, 2019; 2. Patients used vancomycin for anti-infective treatment.

Exclusion criteria

Exclusion criteria: 1. No cases of infection occurred during admission diagnosis or hospitalization; 2. Cases of preventive use of vancomycin; 3. Cases where vancomycin has been used for less than 48 hours.

Design outcomes

Primary

MeasureTime frame
Clinical cure rate;Safety assessment of relevant indicators before and after antibacterial treatment;—

Secondary

MeasureTime frame
Observation indexes reflecting clinical efficacy before and after anti-infection treatment;—

Countries

China

Contacts

Public ContactGe Weihong

Nanjing University Medical School Affiliated Nanjing Drum Tower Hospital

6221230@sina.com+86 13915909299

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026